• Press release
Jun 15, 2022
Damian Marron appointed as Non-Executive Director of Mariposa Therapeutics

Damian Marron is an experienced Board Chair and Non-Executive Director, corporate advisor and former serial CEO with a successful track record of value creation through public and venture capital financing, portfolio planning, M&A, licensing agreements and R&D collaborations, both as an executive and in advisory roles. He has notably specialized in immuno-oncology, cell therapy and orphan diseases. 

"Mariposa has clear expertise in keratin-related science and a young and talented team, with an exciting lead project aimed at bringing the first disease-modifying treatment for the orphan (rare) skin condition, Epidermolysis Bullosa.  As such, I am delighted to join the Board of Directors to use my experience with my fellow directors to guide and support the growth of the company to bring new treatments forward for a variety of keratin-related diseases."

Damian is currently Non-Executive Chair of the Board at Targovax ASA, Cytoseek Ltd and Imophoron Ltd and Non-Executive Director at Cantargia AB, Bone Therapeutics SA and Resolys Bio Inc. He is also Head of Biopharma with Treehill Partners, a global pure-play healthcare advisory firm and is a Biotech Advisor to Mendel Partners. Damian has formerly been Chair of the Board of Directors of PepGen Ltd and the CEO at Agalimmune Ltd, TxCell SA, Cytheris SA, and Trophos SA. He is a pharmacologist and cell biologist by training and spent ten years in big pharma R&D.

Lucy Sykes, Chief Executive Office of Mariposa Therapeutics, said Damian brings an incredible amount of executive biotech experience to further strengthen our Board of Directors and provide invaluable guidance to Mariposa. He has a great breadth of experience in the creation of significant value-enhancing partnerships, and I am delighted to have him on board for this next phase of Mariposa’s journey.